iShares Genomics Immunology and Healthcare ETF
IDNA
5 hedge funds and large institutions have $22.3M invested in iShares Genomics Immunology and Healthcare ETF in 2019 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.
67% more funds holding
Funds holding: 3 → 5 (+2)
9% more capital invested
Capital invested by funds: $20.5M → $22.3M (+$1.88M)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
9.37% less ownership
Funds ownership: 91.89% → 82.52% (-9.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RIA
Realta Investment Advisors
Wilmington,
Delaware
|
+$11.1K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$6.31K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.31M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
BlackRock
New York
| $22M | -$2.31M | -85,000 | -10% |
|
2
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| $359K | – | – | – |
|
|
RIA
3
Realta Investment Advisors
Wilmington,
Delaware
| $12K | +$11.1K | +407 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $9K | +$6.31K | +232 | +341% |
|
|
OPS
5
Orion Portfolio Solutions
Omaha,
Nebraska
| $1K | +$789 | +29 | New |
|
IDNA Hedge Fund Activity: Q4 2019 in Review
5 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in iShares Genomics Immunology and Healthcare ETF (IDNA) for Q4 2019, worth a combined $22.3M — up 9.2% from $20.5M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new IDNA positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Realta Investment Advisors, opening a new position worth an estimated $11.1K. The largest seller was BlackRock, cutting an estimated $2.31M.
- 5 institutional investors held iShares Genomics Immunology and Healthcare ETF (IDNA) as of Q4 2019, up from 3 in Q3 2019.
- Funds reported $22.3M of iShares Genomics Immunology and Healthcare ETF stock for Q4 2019, up 9.2% quarter-over-quarter.
- 2 funds opened new iShares Genomics Immunology and Healthcare ETF positions in Q4 2019 and 0 closed out, a net change of +2 holders.
- The largest iShares Genomics Immunology and Healthcare ETF buyer in Q4 2019 was Realta Investment Advisors, an estimated $11.1K added.
- The largest iShares Genomics Immunology and Healthcare ETF seller in Q4 2019 was BlackRock, an estimated $2.31M sold.
Based on aggregated 13F filings for Q4 2019.